LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

ABSTRACT: A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors

DISEASE(S): Solid Tumor,Carcinoma, Transitional Cell,Colorectal Cancer,Urothelial Carcinoma,Head And Neck Neoplasms,Pancreatic Cancer,Neoplasm Metastasis,Colon Cancer,Colorectal Neoplasms,Head And Neck Cancer,Pancreatic Neoplasms,Metastatic Cancer,Solid Tumors

PROVIDER: 2360612 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR